Monitor the company's ability to secure additional funding beyond this IPO, as current cash will not support pivotal trials. Watch for FDA decisions on Breakthrough Device designation for the stroke recovery system and progress on Orion pivotal trial planning.
Executive Summary
Cortigent, Inc. is a pre-revenue medical device company developing brain implant systems for artificial vision (Orion) and stroke recovery. The company has no commercial revenue, incurred net losses of $3.1 million in 2025, and faces substantial risks including the need for significant additional capital, uncertain clinical trial outcomes, and intense competition from companies like Neuralink. The IPO will raise approximately $13.5 million to fund research and repay parent company debts.
Key Financial Metrics
Key Facts
- Pre-revenue company with no commercial products; Argus II discontinued in 2019
- Net losses of $3.1 million in 2025 and $2.2 million in 2024
- Orion EFS completed with mixed results: 5 of 6 subjects showed improved square localization, but 3 subjects requested explantation
- FDA denied Breakthrough Device designation for stroke recovery system in June 2023
- Vivani Medical will own 77% of voting power post-IPO, creating a controlled company structure
- Only $467,000 in cash as of December 31, 2025, with a working capital deficit of $3.8 million
Financial Impact
The company will use approximately $13.5 million in IPO proceeds to fund Orion research, stroke recovery studies, and repay $1.5 million to parent company Vivani
Risk Factors
- High risk of clinical trial failure given mixed Orion EFS results and explantation requests
- Intense competition from Neuralink and other brain-computer interface companies
- Dependence on parent company Vivani for funding and operational support
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-1/A Filing (Primary) | 0001753926-26-000427 |
| Document: g085138_ex3-1.htm | 0001753926-26-000427 |
| Document: g085138_ex23-2.htm | 0001753926-26-000427 |
| Document: 0001753926-26-000427-index-headers.html | 0001753926-26-000427 |
| Document: 0001753926-26-000427-index.html | 0001753926-26-000427 |
| Document: 0001753926-26-000427.txt | 0001753926-26-000427 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Mar 17, 2026 32w ago | S-1/A | — | awaiting T+20 | — | — |
Mar 3, 2026 34w ago | S-1/A | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers